This study looks at a new drug called daraxonrasib for patients with non-small cell lung cancer (NSCLC) that has RAS mutations. The goal is to see if daraxonrasib is safer and more effective than docetaxel, a standard treatment. Patients will receive either daraxonrasib or docetaxel to see which works better. This study is important for improving treatment options for lung cancer.
The trial's ID number is NCT06881784. It is a Phase 3 study, which means it is looking at how well the treatment works and how safe it is. This study is regulated by the FDA and hopes to include about 590 participants.
Who can join
Adults aged 18 and older can join the study. Both men and women are welcome. Participants must have NSCLC that has been confirmed by a doctor and cannot be treated with surgery or radiation. They should have had one to two prior treatments, including certain types of chemotherapy. Some people cannot join, such as those who have had treatments with RAS-targeted therapy or docetaxel before. The trial team will confirm eligibility for each person.
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into two groups. One group will receive daraxonrasib in oral tablet form. The other group will receive docetaxel through an intravenous infusion. The study aims to find out which treatment helps patients live longer without their cancer getting worse.
Where
This trial is enrolling at 42 locations. Recruiting sites are listed first.
Chief of Thoracic Surgery and Director of the Lung Cancer Program at West Virginia University Cancer Institute. Treats lung cancer and esophageal cancer.
Treats pancreatic cancer, lung cancer and colorectal cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Led the National Lung Screening Trial. Treats lung cancer. Other doctors who help with cancer care, like gastroenterologists, dermatologists, and endocrinologists. Recognized at state, national or international level.